Automate Your Wheel Strategy on EVO
With Tiblio's Option Bot, you can configure your own wheel strategy including EVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EVO
- Rev/Share 2.22
- Book/Share 2.569
- PB 1.2268
- Debt/Equity 0.0
- CurrentRatio 2.0281
- ROIC -0.0955
- MktCap 1119204143.6081
- FreeCF/Share -0.2262
- PFCF -13.9357
- PE -5.4065
- Debt/Assets 0.0
- DivYield 0
- ROE -0.2153
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EVO | Deutsche Bank | Sell | Hold | -- | -- | April 24, 2025 |
| Downgrade | EVO | Jefferies | Buy | Hold | -- | -- | Oct. 7, 2024 |
News
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Published: August 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Evotec SE (NASDAQ:EVO ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Christian Wojczewski - CEO & Management Board Member Cord Dohrmann - Chief Scientific Officer & Member of Management Board Paul Hitchin - CFO & Member of Management Board Volker Braun - Executive VP and Head of Global Investor Relations & ESG Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Charles Robert Weston - RBC Capital Markets, Research Division Christian Ehmann - Warburg Research GmbH Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Fynn Scherzler - Deutsche Bank …
Read More
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
Published: July 30, 2025 by: Accesswire
Sentiment: Neutral
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.
Read More
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Published: July 30, 2025 by: Accesswire
Sentiment: Neutral
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with …
Read More
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Published: July 21, 2025 by: Accesswire
Sentiment: Neutral
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license revenues expected to have a stronger impactthan anticipated Significant cost optimization in excess of initial targets from Priority Reset Shared R&D base businesscontinues to navigate in a challenging market environment H1 2025 Group revenues below expectations; adj. EBITDA broadly in line with expectations Revenue guidance adjusted; R&D and adjusted EBITDA guidance unchanged, reflecting improved revenue mix and cost discipline Evotec confirms itsOutlook 2028 HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE …
Read More
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
Published: July 21, 2025 by: Accesswire
Sentiment: Neutral
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.
Read More
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
Read More
Evotec SE (EVO) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Evotec SE (NASDAQ:EVO ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Conference Call Participants Christian Ehmann - Warburg Research Charles Weston - RBC Joseph Hedden - Rx Securities Fynn Scherzler - Deutsche Bank Douglas Tsao - Wainwright Brendan Smith - TD Cowen Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus Call operator.
Read More
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy building on technology and science leadership: Focus on high-growth, high-value segments, simplifying the business model and fostering operational excellence 2025 Guidance and 2028 Outlook confirmed HAMBURG, DE / ACCESS Newswire / May 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to …
Read More
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral
HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.
Read More
Evotec SE (EVO) Q4 2024 Earnings Call Transcript
Published: April 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Aurélie Dalbiez - Chief People Officer Conference Call Participants Christian Ehmann - Warburg Research Michael Ryskin - Bank of America Charles Weston - RBC Capital Markets Brendan Smith - TD Cowen Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Full-Year Result 2024 Analyst Call. I am Yusuf, the Chorus Call operator.
Read More
Evotec Announces Change in Management Board
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities. Laetitia Rouxel joined Evotec in April 2023 as Chief Financial Officer and member of the Management Board of Evotec.
Read More
Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Elucidata Strengthens Leadership with Former CEO of Evotec and Ex-McKinsey Senior Partner.
Read More
About Evotec SE (EVO)
- IPO Date 2004-02-05
- Website https://www.evotec.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Christian Wojczewski
- Employees 4766